Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Takara Bio USA: Andrew Farmer becomes president and CEO after Carol Lou retires

Carol Lou is retiring after more than two decades as president and CEO of Takara Bio USA. Andrew Farmer, previously chief scientific officer and head of R&D, will assume the position effective Sunday and will advise the company during the transition. Farmer has worked at the company since 1998 and led the development of several product lines, including the NGS product line. Parent company Takara Bio shows a solid liquidity position and a valuation with a price-to-earnings ratio of 16 and a dividend yield of 5.57%; the stock is trading near its 52-week low. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Takara Bio has already paid €0.10 in dividends. The last payout was in June 2025.

Financials

In the last quarter, Takara Bio had revenue of €64.97M and net profit of €108.95K

(EUR)	March 2026	YoY
Revenue	64.97M	-
Gross profit	33.34M	-
Net profit	108.95K	-
EBITDA	8.07M	-

Fundamentals

Metric	Value
Market capitalization	€780.22M
Number of shares	120.42M
52-week high/low	€6.51 - €4.30
Dividends	No
Beta	1.05
P/E ratio	-14.35
PEG ratio	0.03
P/B ratio	1.33
P/S ratio	3.42

Company profile

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.